Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $1.33. Hemispherx BioPharma shares last traded at $1.29, with a volume of 5,074,879 shares.
An institutional investor recently bought a new position in Hemispherx BioPharma stock. A.R.T. Advisors LLC bought a new stake in shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,022 shares of the specialty pharmaceutical company’s stock, valued at approximately $44,000. A.R.T. Advisors LLC owned approximately 0.45% of Hemispherx BioPharma as of its most recent SEC filing.
Hemispherx BioPharma Company Profile (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Story: Why is the price-sales ratio important?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.